Arena Pharmaceuticals Inc. (ARNA)

53.50
0.51 0.94
NASDAQ : Health Technology
Prev Close 54.01
Open 53.35
Day Low/High 53.35 / 54.25
52 Wk Low/High 31.97 / 58.00
Volume 642.67K
Avg Volume 506.20K
Exchange NASDAQ
Shares Outstanding 49.57M
Market Cap 2.77B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Jim Cramer says we'll need to pay close attention to retailers' earnings. Here's your game plan for next week.

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Jim Cramer weighs in on Arena Pharmaceuticals, DaVita, Merck, Abbott Laboratories, IAC Interactive, Yext and more.

Chart of the Day: Arena Pharmaceuticals

Biotech stock Arena is flexing its muscles.

June 28th Options Now Available For Arena Pharmaceuticals (ARNA)

June 28th Options Now Available For Arena Pharmaceuticals (ARNA)

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the June 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new June 28th contracts and identified the following put contract of particular interest.

Arena Pharmaceuticals To Participate In Upcoming Investor Conferences

Arena Pharmaceuticals To Participate In Upcoming Investor Conferences

SAN DIEGO, May 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: UBS Global Healthcare Conference on Monday, May 20, at...

Arena Pharmaceuticals Provides Corporate Update And Reports First Quarter 2019 Financial Results

Arena Pharmaceuticals Provides Corporate Update And Reports First Quarter 2019 Financial Results

- Etrasimod ELEVATE UC Phase 3 Program expected to initiate mid-year targeting significant unmet need in ulcerative colitis

Arena Pharmaceuticals To Release First Quarter 2019 Financial Results And Provide Corporate Update On May 8

Arena Pharmaceuticals To Release First Quarter 2019 Financial Results And Provide Corporate Update On May 8

SAN DIEGO, May 1, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8, 2019, after the close of the U.

Arena Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference On April 10

Arena Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference On April 10

SAN DIEGO, April 3, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARNA, CNTY, GPOR Downgrades: FRPT, JW.A, JW.B, NL, WSR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Arena Pharmaceuticals Presented New Phase 2 Data For Etrasimod And Olorinab At The 14th Congress Of European Crohn's And Colitis Organisation

Arena Pharmaceuticals Presented New Phase 2 Data For Etrasimod And Olorinab At The 14th Congress Of European Crohn's And Colitis Organisation

SAN DIEGO, March 8, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in...

Arena Pharmaceuticals Provides Corporate Update And Reports Fourth Quarter And Full-Year 2018 Financial Results

Arena Pharmaceuticals Provides Corporate Update And Reports Fourth Quarter And Full-Year 2018 Financial Results

- Etrasimod demonstrated clinical response and durable, long-term clinical remission and favorable long-term safety and tolerability in an open-label extension trial

Arena Pharmaceuticals To Present At The 8th Annual SVB Leerink Global Healthcare Conference On February 27

Arena Pharmaceuticals To Present At The 8th Annual SVB Leerink Global Healthcare Conference On February 27

SAN DIEGO, Feb. 21, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals To Announce Fourth Quarter And Full-Year 2018 Financial Results And Provide Corporate Update On February 26

Arena Pharmaceuticals To Announce Fourth Quarter And Full-Year 2018 Financial Results And Provide Corporate Update On February 26

SAN DIEGO, Feb. 20, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Presents Preclinical And Early Clinical Development Data For Olorinab At Crohn's & Colitis Congress

Arena Pharmaceuticals Presents Preclinical And Early Clinical Development Data For Olorinab At Crohn's & Colitis Congress

SAN DIEGO, Feb. 7, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Announces Closing Of Global License Agreement With United Therapeutics For Ralinepag

Arena Pharmaceuticals Announces Closing Of Global License Agreement With United Therapeutics For Ralinepag

SAN DIEGO, Jan. 24, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals To Present At The 37th Annual J.P. Morgan Healthcare Conference On January 10

Arena Pharmaceuticals To Present At The 37th Annual J.P. Morgan Healthcare Conference On January 10

SAN DIEGO, Dec. 19, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni To Board Of Directors

Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni To Board Of Directors

SAN DIEGO, Dec. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Expands Senior Management Team To Support Commercialization And Medical Affairs

Arena Pharmaceuticals Expands Senior Management Team To Support Commercialization And Medical Affairs

SAN DIEGO, Nov. 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Jim Cramer says perception is determining how stocks trade right now -- and there's a lot of negativity.

BP, Arconic, Fiat Chrysler: 'Mad Money' Lightning Round

BP, Arconic, Fiat Chrysler: 'Mad Money' Lightning Round

Jim Cramer take a closer look at BP, Arconic, Fiat Chrysler, Qualcomm, Thermo Fisher, GameStop, Arena Pharmaceuticals and more.

Arena Pharmaceuticals: Don't Fight the Tape or Jim Cramer's Evaluation

Arena Pharmaceuticals: Don't Fight the Tape or Jim Cramer's Evaluation

Let's see what the charts suggest for risk points.

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Jim Cramer explains his post-election play book: Growth stocks may be the way to go.

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Jim Cramer weighs in on Canada Goose, Celgene, BlackRock, Nio, Hospitality Property Trust, Activision Blizzard and more.

First Week Of September 21st Options Trading For Arena Pharmaceuticals (ARNA)

First Week Of September 21st Options Trading For Arena Pharmaceuticals (ARNA)

Investors in Arena Pharmaceuticals Inc saw new options begin trading this week, for the September 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 86 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Sector Steps Up to Provide Some Strong Action for Traders

Biotech Sector Steps Up to Provide Some Strong Action for Traders

The S&P 500 has shown the same pattern for three consecutive days.

Will the Market Go Dead for a While?

Will the Market Go Dead for a While?

The best way to deal with it is to keep on hunting for individual stocks.

The Headlines Are Wrong -- This Is an Extremely Bullish Market

The Headlines Are Wrong -- This Is an Extremely Bullish Market

It is two totally different markets when you compare the small-cap action to the big-cap indices.

TheStreet Quant Rating: C (Hold)